MMP-9 ACTIVITY DETERMINES THE EARLY RESPONSE TO TREATMENT WITH SPIRONOLACTONE IN RESISTANT HYPERTENSION

被引：0
|
作者：
Rodriguez-Sanchez, E. [1 ]
Navarro-Garcia, J. A. [1 ]
Aceves-Ripoll, J. [1 ]
Alvarez-Llamas, G. [2 ]
De la Cuesta, F. [3 ]
Segura, J. [4 ]
Barderas, M. G. [3 ]
Ruilope, L. M. [1 ,4 ]
Ruiz-Hurtado, G. [1 ,4 ]
机构：
[1] Hosp 12 Octubre, Inst Res, Cardiorenal Translat Lab, Madrid, Spain
[2] IIS Fdn Jimenez Diaz, Dept Immunol, Madrid, Spain
[3] Hosp Nacl Paraplej, Dept Vasc Physiopathol, Toledo, Spain
[4] Hosp Univ 12 Octubre, Hypertens Unit, Madrid, Spain
来源：
JOURNAL OF HYPERTENSION | 2018年 / 36卷
关键词：
D O I：
10.1097/01.hjh.0000539873.19916.d2
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：E298 / E298
页数：1
相关论文
共 50 条
  • [1] Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters
    Rodriguez-Sanchez, Elena
    Navarro-Garcia, Jose Alberto
    Aceves-Ripoll, Jennifer
    Gonzalez-Lafuente, Laura
    Baldan-Martin, Montserrat
    de la Cuesta, Fernando
    Alvarez-Llamas, Gloria
    Barderas, Maria G.
    Segura, Julian
    Ruilope, Luis M.
    Ruiz-Hurtado, Gema
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (01) : 68 - 76
  • [2] OBESITY-DEPENDENT EFFECTS ON MMP-9 LEVELS IN RESISTANT HYPERTENSION
    Ritter, A.
    Faria, A.
    Modolo, R.
    Barbaro, N.
    Sabbatini, A.
    Correa, N.
    Brunelli, V.
    Pires, N.
    Almeida, A.
    Moreno, H.
    JOURNAL OF HYPERTENSION, 2016, 34 : E171 - E171
  • [3] Role Of MMP-2 and MMP-9 in Resistance to Drug Therapy in Patients with Resistant Hypertension
    Lacerda, Leandro
    de Faria, Ana Paula
    Fontana, Vanessa
    Moreno, Heitor
    Sandrim, Valeria
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2015, 105 (02) : 168 - 174
  • [4] MMP-9 elevation in the early response to olfactory nerve injury
    Costanzo, R. M.
    Perrino, L. A.
    Kobayashi, M.
    CHEMICAL SENSES, 2006, 31 (05) : A137 - A137
  • [5] β-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity
    Michaluk, Piotr
    Kolodziej, Lukasz
    Mioduszewska, Barbara
    Wilczynski, Grzegorz M.
    Dzwonek, Joanna
    Jaworski, Jacek
    Gorecki, Dariusz C.
    Ottersen, Ole Petter
    Kaczmarek, Leszek
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (22) : 16036 - 16041
  • [6] Development of Brain Targeting Peptide Based MMP-9 Inhibiting Nanoparticles for the Treatment of Brain Diseases with Elevated MMP-9 Activity
    Islam, Yamir
    Khalid, Aneesa
    Pluchino, Stefano
    Sivakumaran, Muttuswamy
    Teixido, Meritxell
    Leach, Andrew
    Fatokun, Amos A.
    Downing, James
    Coxon, Christopher
    Ehtezazi, Touraj
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 109 (10) : 3134 - 3144
  • [7] MMP-9 is a candidate marker of response to treatment with dabrafenib in melanoma cells
    Candido, Saverio
    McCubrey, James A.
    Salemi, Rosella
    Pezzino, Franca Maria
    Malaponte, Grazia
    Libra, Massimo
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S114 - S114
  • [8] Spironolactone and Doxazosin Treatment in Patients With Resistant Hypertension
    Rodilla, Enrique
    Costa, Jose A.
    Perez-Lahiguera, Francisco
    Baldo, Emilio
    Gonzalez, Carmen
    Pascual, Jose M.
    REVISTA ESPANOLA DE CARDIOLOGIA, 2009, 62 (02): : 158 - 166
  • [9] Response MMP-9 in platelets: maybe, maybe not
    Falcinelli, Emanuela
    Bury, Loredana
    Tolley, Neal
    Malvestiti, Marco
    Cecchetti, Luca
    Weyrich, Andy
    Gresele, Paolo
    BLOOD, 2011, 118 (24) : 6471 - 6473
  • [10] Crosstalk between obesity and MMP-9 in cardiac remodelling -a cross-sectional study in apparent treatment-resistant hypertension
    Versuti Ritter, Alessandra Mileni
    de Faria, Ana Paula
    Barbaro, Natalia
    Sabbatini, Andrea Rodrigues
    Correa, Nathalia Batista
    Brunelli, Veridiana
    Amorim, Rivadavio
    Modolo, Rodrigo
    Moreno, Heitor
    BLOOD PRESSURE, 2017, 26 (02) : 122 - 129
12345